Poland· PL-100468599
Nucala
A mepolizumab product containing mepolizumabum, registered in Poland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Mepolizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC R03DX09 (mepolizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Mepolizumab · ATC R03DX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Mepolizumabum
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Poland (PL)
- ATC code
- R03DX09
- ATC class
- Mepolizumab
- Defined daily dose
- 3.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991483296
- gtin05909991483302
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mepolizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNUCALAGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumNucala 40 mgGlaxoSmithKline Trading Services
- SpainNUCALA 40 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAGlaxosmithkline Trading Services Limited
- IcelandNucalaGlaxoSmithKline Trading Services Limited
- NorwayNucalaGlaxoSmithKline Trading Services Limited
- SwedenNucala 40 mg Injektionsvätska, lösning i förfylld sprutaGlaxoSmithKline Trading Services Ltd
- ItalyNUCALA*1 flaconcino SC 100 mgGLAXOSMITHKLINE TRAD.SERV.LTD
- FinlandNucalaGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nucala
- Liechtenstein · Nucala
- Norway · Nucala
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf72922a-083b-4f7b-a841-69cbb6849203 GET /v1/drugs/bf72922a-083b-4f7b-a841-69cbb6849203?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "40 mg",
"packaging": "05909991483296 ¦ Rpz ¦ EU/1/15/1043/010 ¦ 144991\n3 amp.-strzyk. 0,4 ml\n05909991483302 ¦ Rpz ¦ EU/1/15/1043/009 ¦ 144992\n1 amp.-strzyk. 0,4 ml",
"substance": "Mepolizumabum 40 mg",
"common_name": "Mepolizumabum",
"pl_product_id": "100468599",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about mepolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.